Methods and formulations to treat mitochondrial dysfunction

US12377077B2 · kind B2 · utility

Assignee

• The Board of Trustees of the Leland Stanford Junior University · US

Inventors

• Tereza Moore · Palo Alto, US
• Tina Cowan · Palo Alto, US
• Gregory M. Enns · Palo Alto, US
• Mehrdad Shamloo · Stanford, US
• Michael J. Green · Skillman, US
• Alam Jahangir · San Jose, US
• Rolando E. Yanes · Santa Clara, US

Key dates

• Filing date: Dec 31, 2019
• Grant date: Aug 5, 2025
• Expiry date: Dec 7, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D493/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Methods of treatment and pharmaceutical formulations configured to treat primary and secondary mitochondrial dysfunction are provided. The methods and treatments use an agonist of AMPK. The agonist activates AMPK to activate ATP-producing pathways and inhibiting ATP-consuming pathways, thus allowing for the alleviation of symptoms associated with mitochondrial dysfunctions.